Why the study?
Despite available lipid-lowering drugs, few patients achieve target lipid levels, motivating the systematization of data on innovative targeted lipid-lowering therapies.
Design
Review
Authors
Loading...
Targeted hyperlipidemia therapies may overcome adherence and access barriers; leaves open real-world effects on LDL-C target attainment.
Novel targeted therapies for hyperlipidemia, including RNA-based and monoclonal antibody treatments, provide new avenues for achieving lipid targets and reducing cardiovascular risk.
Чубыкина et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: